RCT for prophylaxis with ivermectin showing a significant reduction in cases with treatment.
Relative risk of COVID-19 case RR 0.2, p
This paper also reports a treatment study .
Elgazzar et al., 11/13/2020, Randomized Controlled Trial, Egypt, Africa, preprint, 6 authors, dosage 400μg/kg weekly.
risk of COVID-19 case, 80.0% lower, RR 0.20, p = 0.03, treatment 2 of 100 (2.0%), control 10 of 100 (10.0%).
Effect extraction follows pre-specified rules prioritizing more serious
outcomes. For an individual study the most serious outcome may have a smaller
number of events and lower statistical signficance, however this provides the
strongest evidence for the most serious outcomes when combining the results of